Enveric Biosciences Inc (ENVB) Stock Price, Quote & News

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology

Sector: Healthcare

Phone: 239-302-1707

Website: www.enveric.com

Address:

4851 Tamiami Trail N, Suite 200, Naples, United States

Luckyjs38 Aug. 8 at 4:23 PM

$ENVB This will go parabolic next week . mark this post 👀 HODL

1 · Reply

Luckyjs38 Aug. 7 at 8:19 PM

$ENVB

0 · Reply

Invescent Aug. 7 at 6:08 PM

$ENVB... time to pump soon dead money for some time.

0 · Reply

Luckyjs38 Aug. 7 at 2:01 PM

$ENVB Going all in ❤️

0 · Reply

Luckyjs38 Aug. 5 at 4:19 PM

$ENVB

0 · Reply

Luckyjs38 Aug. 4 at 11:17 PM

$ENVB 🇺🇸 Enveric will change the world for the better. Its about making peoples lives better. their patented ai platform coupled with World renowned medical doctors are extracting molecules that show vast potential for treating anxiety, depression,ptsd, and many other ailments. Gods gift to mankind are mushrooms i believe especially psilocybin and other psychoactive organic compounds can be derived and made in to life saving medications all from mother nature with minimal side effects… Lets see this is my thesis

0 · Reply

Luckyjs38 Aug. 4 at 11:11 PM

$ENVB

0 · Reply

Love_To_Learn Aug. 1 at 11:12 AM

$MWYN relaying data to beloveds old friend $ENVB

0 · Reply

BigWillyStyle Jul. 31 at 2:09 PM

$ENVB This one will pop today...especially on the heals of the run up on ATAI and PBM.

0 · Reply

ManikMind Jul. 31 at 12:06 AM

$GNLN $UGRO $ENVB Been around for years. Not leaving. 😆🍀✌️#legalizeit #NORML

0 · Reply

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 15, 2025, 9:03 AM EDT - 24 days ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jun 24, 2025, 9:03 AM EDT - 6 weeks ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 16, 2025, 10:46 AM EDT - 7 weeks ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 10, 2025, 9:03 AM EDT - 2 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 3, 2025, 9:00 AM EDT - 2 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

May 28, 2025, 9:03 AM EDT - 2 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 20, 2025, 8:00 AM EDT - 2 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 14, 2025, 4:15 PM EDT - 3 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Mar 31, 2025, 8:00 AM EDT - 4 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 17, 2025, 1:40 PM EDT - 5 months ago

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 6, 2025, 10:00 AM EST - 5 months ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Feb 27, 2025, 9:30 AM EST - 5 months ago

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 25, 2025, 1:30 PM EST - 5 months ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 4, 2025, 8:00 AM EST - 6 months ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 3, 2025, 5:00 PM EST - 6 months ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 6 months ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 4:01 PM EST - 6 months ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 6, 2025, 8:30 AM EST - 7 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Dec 2, 2024, 8:00 AM EST - 8 months ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Nov 25, 2024, 9:00 AM EST - 9 months ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 14, 2024, 4:05 PM EST - 9 months ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 12, 2024, 9:00 AM EST - 9 months ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 4, 2024, 10:36 AM EST - 9 months ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Oct 15, 2024, 8:00 AM EDT - 10 months ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Sep 26, 2024, 8:30 AM EDT - 11 months ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Sep 25, 2024, 8:30 AM EDT - 11 months ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Aug 12, 2024, 5:30 PM EDT - 1 year ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Jul 15, 2024, 9:02 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Patent Granted for Drug Candidate

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

MBIO

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

May 30, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Participate in BIO International Convention 2024

May 15, 2024, 6:00 AM EDT - 1 year ago

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 14, 2024, 10:35 AM EDT - 1 year ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 8, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Feb 29, 2024, 7:00 AM EST - 1 year ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Feb 23, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Feb 21, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Jan 3, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Dec 29, 2023, 8:52 AM EST - 1 year ago

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Dec 28, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Dec 27, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Dec 20, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

Luckyjs38 Aug. 8 at 4:23 PM

$ENVB This will go parabolic next week . mark this post 👀 HODL

1 · Reply

Luckyjs38 Aug. 7 at 8:19 PM

$ENVB

0 · Reply

Invescent Aug. 7 at 6:08 PM

$ENVB... time to pump soon dead money for some time.

0 · Reply

Luckyjs38 Aug. 7 at 2:01 PM

$ENVB Going all in ❤️

0 · Reply

Luckyjs38 Aug. 5 at 4:19 PM

$ENVB

0 · Reply

Luckyjs38 Aug. 4 at 11:17 PM

0 · Reply

Luckyjs38 Aug. 4 at 11:11 PM

$ENVB

0 · Reply

Love_To_Learn Aug. 1 at 11:12 AM

$MWYN relaying data to beloveds old friend $ENVB

0 · Reply

BigWillyStyle Jul. 31 at 2:09 PM

$ENVB This one will pop today...especially on the heals of the run up on ATAI and PBM.

0 · Reply

ManikMind Jul. 31 at 12:06 AM

$GNLN $UGRO $ENVB Been around for years. Not leaving. 😆🍀✌️#legalizeit #NORML

0 · Reply

RayIngersoll776 Jul. 30 at 5:21 PM

$ENVB talks mental health innovation, while AITX is transforming physical security with real products and a subscription model. At 4× revenue, it’s far cheaper than $PLTR (100×) and $AAPL (7.5×) — and growing faster.

0 · Reply

_Roberto Jul. 29 at 3:19 PM

$ENVB patents?

0 · Reply

Fib7867 Jul. 29 at 4:35 AM

#myENVBanalysis $ENVB

0 · Reply

Luckyjs38 Jul. 24 at 2:49 PM

$ENVB 🇺🇸 Enveric will change the witod for the better. its about making peoples lives better. ❤️

0 · Reply

BioTuesdays Jul. 23 at 4:20 PM

USPTO grants Enveric second patent allowance for next-gen mescaline derivatives $ENVB https://biotuesdays.com/2025/07/23/uspto-grants-enveric-second-patent-allowance-for-next-gen-mescaline-derivatives/

0 · Reply

Luckyjs38 Jul. 23 at 3:05 PM

$ENVB glad i bought more here on that dip of bullish news . shorts are in trouble here its just a matter of time

0 · Reply